BRPI0620586A2 - formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento - Google Patents

formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento Download PDF

Info

Publication number
BRPI0620586A2
BRPI0620586A2 BRPI0620586-0A BRPI0620586A BRPI0620586A2 BR PI0620586 A2 BRPI0620586 A2 BR PI0620586A2 BR PI0620586 A BRPI0620586 A BR PI0620586A BR PI0620586 A2 BRPI0620586 A2 BR PI0620586A2
Authority
BR
Brazil
Prior art keywords
glp
administration
agents
formulation
grp
Prior art date
Application number
BRPI0620586-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Steven C Quay
Henry R Costantino
Michael V Templin
Alexis Kays Leonard
Mary S Kleppe
Joshua O Sestak
Original Assignee
Nastech Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/293,676 external-priority patent/US20060074025A1/en
Priority claimed from PCT/US2006/008928 external-priority patent/WO2007061434A2/en
Application filed by Nastech Pharm Co filed Critical Nastech Pharm Co
Publication of BRPI0620586A2 publication Critical patent/BRPI0620586A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BRPI0620586-0A 2005-12-02 2006-12-01 formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento BRPI0620586A2 (pt)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US11/293,676 2005-12-02
US11/293,676 US20060074025A1 (en) 2003-12-26 2005-12-02 Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US77646406P 2006-02-24 2006-02-24
US60/776,464 2006-02-24
USPCT/US06/8928 2006-03-03
PCT/US2006/008928 WO2007061434A2 (en) 2005-11-10 2006-03-10 A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
US80440606P 2006-06-09 2006-06-09
US60/804,406 2006-06-09
US80454306P 2006-06-12 2006-06-12
US60/804,543 2006-06-12
US80519106P 2006-06-19 2006-06-19
US60/805,191 2006-06-19
PCT/US2006/061503 WO2007065156A2 (en) 2005-12-02 2006-12-01 Pharmaceutical formulation for increased epithelial permeability of glucose-regulating peptide

Publications (1)

Publication Number Publication Date
BRPI0620586A2 true BRPI0620586A2 (pt) 2011-11-16

Family

ID=38005475

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0620586-0A BRPI0620586A2 (pt) 2005-12-02 2006-12-01 formulação farmacêutica aquosa para administração intranasal e uso de uma formulação farmacêutica aquosa para elaborar um medicamento

Country Status (5)

Country Link
EP (1) EP1965828A2 (de)
JP (1) JP2009518315A (de)
BR (1) BRPI0620586A2 (de)
MX (1) MX2008007075A (de)
WO (1) WO2007065156A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008326800A1 (en) 2007-11-16 2009-05-28 Baylor College Of Medicine Phospholipid compositions and uses thereof
WO2010054326A2 (en) 2008-11-07 2010-05-14 The General Hospital Corporation C-terminal fragments of glucagon-like peptide-1 (glp-1)
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
US9040481B2 (en) 2010-11-02 2015-05-26 The General Hospital Corporation Methods for treating steatotic disease
MX348831B (es) * 2011-03-04 2017-06-30 Gruenenthal Gmbh Administración parenteral de tapentadol.
EP2526971A1 (de) 2011-05-25 2012-11-28 ArisGen SA Mukosale Freisetzung von Arzneimitteln
EP2729157B1 (de) 2011-07-06 2019-01-16 The General Hospital Corporation Ein pentapeptid aus dem c-terminus des glucagon-like peptids-1 (glp-1) zur verwendung in der behandlung
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
JP2016506401A (ja) 2012-12-21 2016-03-03 サノフイ 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体
CN103405753B (zh) * 2013-08-13 2016-05-11 上海仁会生物制药股份有限公司 稳定的促胰岛素分泌肽水针药物组合物
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080150B1 (de) 2013-12-13 2018-08-01 Sanofi Exendin-4-peptidanaloga als duale glp-1/gip-rezeptoragonisten
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TN2017000349A1 (en) 2015-02-17 2019-01-16 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
CN117323410A (zh) * 2022-06-30 2024-01-02 深圳翰宇药业股份有限公司 一种多肽药物溶液制剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
US7312196B2 (en) * 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
IL161446A0 (en) * 2001-11-26 2004-09-27 Daiichi Suntory Pharma Co Ltd Medicinal compositions for nasal absorption
BR0314996A (pt) * 2002-10-02 2005-08-09 Zealand Pharma As Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides

Also Published As

Publication number Publication date
EP1965828A2 (de) 2008-09-10
WO2007065156A3 (en) 2007-07-19
WO2007065156B1 (en) 2007-09-13
MX2008007075A (es) 2008-11-12
WO2007065156A2 (en) 2007-06-07
JP2009518315A (ja) 2009-05-07

Similar Documents

Publication Publication Date Title
AU2004312043B2 (en) Intranasal administration of glucose-regulating peptides
EP1951198B1 (de) Intranasale verabreichung von schnell wirkendem insulin
US9993425B2 (en) Compositions for intranasal delivery of human insulin and uses thereof
US20080318837A1 (en) Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20060210614A1 (en) Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318861A1 (en) Mucosal Delivery of Stabilized Formulations of Exendin
US20060074025A1 (en) Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
MX2008007075A (es) Formulacion farmaceutica para incrementar la permeabilidad epitelial por peptido regulador de glucosa.
WO2005115441A2 (en) Compositions and methods for enhanced mucosal delivery of parathyroid hormone
WO2007146448A1 (en) Pharmaceutical formulations of glp-1 derivatives
US20060069021A1 (en) Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
WO2007061434A2 (en) A pharmaceutical formulation of glp-1 and its use for treating a metabolic syndrome
CN101340893B (zh) 速效胰岛素的鼻内施用
US20070185035A1 (en) Enhanced mucosal administration of neuroprotective peptides
US20070213270A1 (en) Peptide yy formulations having increased stability and resistance to microbial agents
ES2345509T3 (es) Administracion intranasal de insulina de accion rapida.
MX2008004980A (es) Administracion intranasal de insulina de rapida accion

Legal Events

Date Code Title Description
B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: NASTECH PHARMACEUTICAL COMPANY INC. (US)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 018090006130/SP DE 06/02/2009,E NECESSARIO APRESENTAR O DOCUMENTO DE ALTERACAO DE NOME COM A DEVIDA LEGALIZACAO CONSULAR, BEM COMO A GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25E Requested change of name of applicant rejected

Owner name: NASTECH PHARMACEUTICAL COMPANY INC. (US)

B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6A ANUIDADE

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2214 DE 11/06/2013.